> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regulatory Review Period for Dog Pain Drug was 2,092 Days
- URL: https://www.fdaweb.com/regulatory-review-period-for-dog-pain-drug-was-2-092-days/
- Published: 2017-08-21T12:00:00.000Z
- Updated: 2026-09-14T22:42:23.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5139425

*Federal Register* notice: FDA has determined for patent restoration purposes the regulatory review period for Acrux DDS Pty. Ltd.’s Recuvyra (fentanyl), indicated for controlling postoperative pain associated with surgical procedures in dogs. The applicable regulatory review period for Recuvyra is 2,092 days, which includes 2,037 days during the testing phase and 55 days during the approval phase. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2017-08-21/pdf/2017-17566.pdf?ref=fdaweb.com).